Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
oncology (100) 100
female (90) 90
middle aged (87) 87
aged (86) 86
adult (79) 79
chemotherapy (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
index medicus (50) 50
treatment outcome (41) 41
breast cancer (40) 40
cancer (40) 40
male (38) 38
breast neoplasms - drug therapy (37) 37
paclitaxel (33) 33
prognosis (32) 32
aged, 80 and over (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
survival (26) 26
breast neoplasms - pathology (25) 25
carcinoma (25) 25
disease-free survival (25) 25
human (24) 24
article (23) 23
paclitaxel - administration & dosage (23) 23
trial (23) 23
epirubicin (22) 22
therapy (21) 21
priority journal (20) 20
antineoplastic combined chemotherapy protocols (19) 19
research (19) 19
survival analysis (19) 19
metastasis (18) 18
cancer survival (17) 17
carboplatin (17) 17
cisplatin (17) 17
clinical trial (17) 17
drug administration schedule (17) 17
medicine (17) 17
research article (17) 17
breast neoplasms - mortality (16) 16
neoplasm staging (16) 16
antineoplastic agents (15) 15
breast neoplasms (15) 15
carboplatin - administration & dosage (15) 15
care and treatment (15) 15
clinical trials (15) 15
doxorubicin (15) 15
major clinical study (15) 15
medicine & public health (15) 15
melanoma (15) 15
neoplasm metastasis (15) 15
young adult (15) 15
cyclophosphamide (14) 14
immunohistochemistry (14) 14
melanoma - drug therapy (14) 14
retrospective studies (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
chemotherapy, adjuvant (13) 13
drug therapy (13) 13
fluorouracil (13) 13
neutropenia (13) 13
advanced cancer (12) 12
analysis (12) 12
anemia (12) 12
antineoplastic agents - therapeutic use (12) 12
fluorouracil - administration & dosage (12) 12
gene expression (12) 12
phase-ii (12) 12
survival rate (12) 12
tumors (12) 12
controlled study (11) 11
greece (11) 11
hematology, oncology and palliative medicine (11) 11
patients (11) 11
protein expression (11) 11
thrombocytopenia (11) 11
adjuvant chemotherapy (10) 10
alopecia (10) 10
anthracyclines (10) 10
antimitotic agents (10) 10
biomarkers (10) 10
cancer patients (10) 10
diarrhea (10) 10
disease progression (10) 10
epirubicin - administration & dosage (10) 10
genetic aspects (10) 10
health aspects (10) 10
hospitals (10) 10
medical research (10) 10
neoplasms (10) 10
receptor, erbb-2 - metabolism (10) 10
recombinant granulocyte colony stimulating factor (10) 10
biomarkers, tumor - metabolism (9) 9
breast neoplasms - genetics (9) 9
breast neoplasms - metabolism (9) 9
colorectal cancer (9) 9
docetaxel (9) 9
drug efficacy (9) 9
erbb-2 protein (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
by Pectasides, Dimitrios and Papaxoinis, George and Kalogeras, Konstantine T and Eleftheraki, Anastasia G and Xanthakis, Ioannis and Makatsoris, Thomas and Samantas, Epaminondas and Varthalitis, Ioannis and Papakostas, Pavlos and Nikitas, Nikitas and Papandreou, Christos N and Pentheroudakis, George and Timotheadou, Eleni and Koutras, Angelos and Sgouros, Joseph and Bafaloukos, Dimitrios and Klouvas, George and Economopoulos, Theofanis and Syrigos, Konstantinos N and Fountzilas, George
BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
by Gogas, Helen and Ioannovich, John and Dafni, Urania and Stavropoulou-Giokas, Catherine and Frangia, Konstantina and Tsoutsos, Dimosthenis and Panagiotou, Petros and Polyzos, Aristidis and Papadopoulos, Othonas and Stratigos, Alexandros and Markopoulos, Christos and Bafaloukos, Dimitrios and Pectasides, Dimitrios and Fountzilas, George and Kirkwood, John M
The New England Journal of Medicine, ISSN 0028-4793, 02/2006, Volume 354, Issue 7, pp. 709 - 718
In a prospective trial of interferon alfa-2b for malignant melanoma, autoantibodies and clinical manifestations of autoimmunity during treatment were... 
INTERLEUKIN-2 | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | THERAPY | HIGH-DOSE INTERFERON | THYROID-DYSFUNCTION | CHRONIC HEPATITIS-C | CUTANEOUS MELANOMA | CANCER | RENAL-CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Autoimmunity | Recurrence | Prognosis | Skin Neoplasms - drug therapy | Follow-Up Studies | Autoantibodies - blood | Humans | Middle Aged | Male | Recombinant Proteins | Skin Neoplasms - mortality | Adult | Female | Chemotherapy, Adjuvant | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - immunology | Interferon-alpha - therapeutic use | Proportional Hazards Models | Analysis of Variance | Melanoma - immunology | Melanoma - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Melanoma - mortality | Melanoma | Interferon | Dosage and administration | Research | Drug therapy | Clinical trials | Oncology | Cytokines | Hypothyroidism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
by Linardou, Helena, PhD and Dahabreh, Issa J, MD and Kanaloupiti, Dimitra, MD and Siannis, Fotios, PhD and Bafaloukos, Dimitrios, MD and Kosmidis, Paris, MD and Papadimitriou, Christos A, MD and Murray, Samuel, Dr
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 10, pp. 962 - 972
Summary Background Somatic mutations of the k-RAS oncogene have been assessed as a mechanism of de-novo resistance to epidermal growth factor receptor (EGFR)... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | PHASE-III TRIAL | DISEASE-CONTROL | PROGNOSTIC-FACTOR | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | KRAS MUTATION | IN-SITU HYBRIDIZATION | ACQUIRED-RESISTANCE | GEFITINIB TREATMENT | GENE COPY NUMBER | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Colonic Neoplasms - drug therapy | Humans | Antibodies, Monoclonal - therapeutic use | Colonic Neoplasms - secondary | Antineoplastic Agents - therapeutic use | Genetic Markers | Drug Resistance, Neoplasm - genetics | Likelihood Functions | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Genes, ras
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
by Pentheroudakis, George and Kotoula, Vassiliki and De Roock, Wendy and Kouvatseas, George and Papakostas, Pavlos and Makatsoris, Thomas and Papamichael, Demetris and Xanthakis, Ioannis and Sgouros, Joseph and Televantou, Despina and Kafiri, Georgia and Tsamandas, Athanassios C and Razis, Evangelia and Galani, Eleni and Bafaloukos, Dimitrios and Efstratiou, Ioannis and Bompolaki, Iliada and Pectasides, Dimitrios and Pavlidis, Nicholas and Tejpar, Sabine and Fountzilas, George
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, pp. 49 - 49
Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis... 
PI3K gene mutations | Biomarkers | EGFR ligands | BRAF | KRAS | Cetuximab | Epidermal growth factor receptor | 1ST-LINE TREATMENT | LEUCOVORIN | EPIREGULIN | STATISTICS | FLUOROURACIL | CHEMOTHERAPY | BREAST-CANCER | PANITUMUMAB | MUTATION STATUS | ONCOLOGY | Colorectal Neoplasms - genetics | Humans | Middle Aged | Glycoproteins - metabolism | Male | Antineoplastic Agents - therapeutic use | Epiregulin | Amphiregulin | RNA, Messenger - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | EGF Family of Proteins | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Colorectal Neoplasms - metabolism | Genes, ras - genetics | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Epidermal Growth Factor - metabolism | Genotype | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phosphatidylinositol 3-Kinase - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - secondary | Aged | Drugs | Adverse and side effects | Research | Drug therapy | Patient outcomes | Colorectal cancer | Medical research | Care and treatment | Genes | Metastasis | Antineoplastic agents | Formaldehyde | Antimitotic agents | Messenger RNA | Epidermal growth factor | Codon | Gene mutations | Analysis | Monoclonal antibodies | Medicine, Experimental | Genetic aspects | Biological markers | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
by Papadimitriou, Christos A and Papakostas, Pavlos and Karina, Maria and Malettou, Lia and Dimopoulos, Meletios A and Pentheroudakis, George and Samantas, Epaminontas and Bamias, Aristotelis and Miliaras, Dimosthenis and Basdanis, George and Xiros, Nikolaos and Klouvas, George and Bafaloukos, Dimitrios and Kafiri, Georgia and Papaspirou, Irene and Pectasides, Dimitrios and Karanikiotis, Charisios and Economopoulos, Theofanis and Efstratiou, Ioannis and Korantzis, Ippokratis and Pisanidis, Nikolaos and Makatsoris, Thomas and Matsiakou, Fotini and Aravantinos, Gerasimos and Kalofonos, Haralabos P and Fountzilas, George
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
by Koutras, Angelos and Lazaridis, Georgios and Koliou, Georgia-Angeliki and Kouvatseas, George and Christodoulou, Christos and Pectasides, Dimitrios and Kotoula, Vassiliki and Batistatou, Anna and Bobos, Mattheos and Tsolaki, Eleftheria and Papadopoulou, Kyriaki and Pentheroudakis, George and Papakostas, Pavlos and Pervana, Stavroula and Petraki, Kalliopi and Chrisafi, Sofia and Razis, Evangelia and Psyrri, Amanda and Bafaloukos, Dimitrios and Kalogeras, Konstantine T and Kalofonos, Haralambos P and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0207707
In the current study, we performed a complete analysis, with four different methods, of all four HER family receptors, in a series of patients with metastatic... 
BENEFIT | MESSENGER-RNA EXPRESSION | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | PROTEIN EXPRESSION | QUANTITATIVE PCR | GROWTH-FACTOR RECEPTORS | PREDICTIVE-VALUE | HER2 | EGFR | IMMUNOHISTOCHEMISTRY | Immunohistochemistry | Care and treatment | Prognosis | RNA | Oncology, Experimental | Genes | Development and progression | Breast cancer | Metastasis | Research | Antineoplastic agents | Antimitotic agents | Cancer patients | Cancer | Health sciences | Laboratories | Copy number | Fluorescence | Oncology | Hybridization | Multivariate analysis | Paraffin | Subgroups | Metastases | Proteins | Receptors | Fluorescence in situ hybridization | HER protein | Paraffins | Medical research | Evaluation | Internal medicine | Epidermal growth factor receptors | Health risks | Gene expression | Patients | Survival | ErbB-2 protein | Medicine | Pathology | Gene amplification | Chemotherapy | Hospitals | Breast | Protein expression | PTEN protein | Trastuzumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
by Fountzilas, George and Dafni, Urania and Bobos, Mattheos and Batistatou, Anna and Kotoula, Vassiliki and Trihia, Helen and Malamou-Mitsi, Vassiliki and Miliaras, Spyros and Chrisafi, Sofia and Papadopoulos, Savvas and Sotiropoulou, Maria and Filippidis, Theodoros and Gogas, Helen and Koletsa, Triantafyllia and Bafaloukos, Dimitrios and Televantou, Despina and Kalogeras, Konstantine T and Pectasides, Dimitrios and Skarlos, Dimosthenis V and Koutras, Angelos and Dimopoulos, Meletios A
PLoS ONE, ISSN 1932-6203, 06/2012, Volume 7, Issue 6, p. e37946
Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in... 
PHASE-III TRIAL | COOPERATIVE ONCOLOGY GROUP | NEOADJUVANT CHEMOTHERAPY | MULTIDISCIPLINARY SCIENCES | PROTEIN EXPRESSION | TISSUE MICROARRAYS | BRAIN METASTASES | RISK | DENSE SEQUENTIAL CHEMOTHERAPY | PROGNOSTIC VALUE | DOCETAXEL | Immunohistochemistry | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Methotrexate - therapeutic use | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Cyclophosphamide - therapeutic use | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Young Adult | Disease-Free Survival | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Epirubicin - therapeutic use | Keratin-5 - metabolism | Adult | Female | Aged | Anthracyclines - therapeutic use | Medical research | Anthracyclines | Estrogen | Adjuvant treatment | Breast cancer | Metastasis | Keratin | Paclitaxel | Medicine, Experimental | Rankings | Progesterone | Health aspects | Cancer | Enrichment | Brain | Cytokeratin | Laboratories | Liver | Estrogens | Clinical trials | Estrogen receptors | Oncology | Nervous system | Paraffin | Cancer therapies | Subgroups | Metastases | Proteins | Cell growth | Mastectomy | Epirubicin | Drug dosages | Risk groups | Epidermal growth factor receptors | Health risks | Patients | Survival | ErbB-2 protein | Medicine | Studies | Pathology | Chemotherapy | Brain research | Hospitals | Anthracycline | Collaboration | Medical prognosis | Biomarkers | Trastuzumab | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study
by Bafaloukos, Dimitrios and Linardou, Helena and Aravantinos, Gerasimos and Papadimitriou, Christos and Bamias, Aristotelis and Fountzilas, George and Kalofonos, Haralabos P and Kosmidis, Paris and Timotheadou, Eleni and Makatsoris, Thomas and Samantas, Epaminondas and Briasoulis, Evangelos and Christodoulou, Christos and Papakostas, Pavlos and Pectasides, Dimitrios and Dimopoulos, Athanasios M
BMC Medicine, ISSN 1741-7015, 01/2010, Volume 8, Issue 1, pp. 3 - 3
Background: Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was... 
WOMEN | 2ND-LINE | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | CLINICAL-TRIAL | RECURRENT | OVARIALKARZINOM AGO-OVAR | SCHEDULE | CARCINOMA | EPITHELIAL OVARIAN | CHEMOTHERAPY | Prognosis | Ovarian Neoplasms - diagnosis | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Polyethylene Glycols - adverse effects | Treatment Outcome | Polyethylene Glycols - administration & dosage | Carboplatin - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Aged | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - adverse effects | Doxorubicin - administration & dosage | Antimitotic agents | Research | Antineoplastic agents | Drug therapy | Health aspects | Ovarian cancer | Studies | Chemotherapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
by Dimitrios Pectasides and Urania Dafni and Dimitrios Bafaloukos and Dimosthenis Skarlos and Aristidis Polyzos and Dimosthenis Tsoutsos and Haralambos Kalofonos and George Fountzilas and Petros Panagiotou and George Kokkalis and Othon Papadopoulos and Ourania Castana and Stefanos Papadopoulos and Elias Stavrinidis and Georgia Vourli and John Ioannovich and Helen Gogas
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 6, pp. 939 - 944
Purpose A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique for the incorporation of an induction phase of maximally tolerated... 
TRIAL | THERAPY | ONCOLOGY | AMERICAN JOINT COMMITTEE | COOPERATIVE-ONCOLOGY-GROUP | Skin Neoplasms - drug therapy | Drug Administration Schedule | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Interferon-alpha - administration & dosage | Time Factors | Melanoma - drug therapy | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Chemotherapy, Adjuvant | Melanoma - surgery | Skin Neoplasms - surgery | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
by Fostira, Florentia and Tsitlaidou, Marianthi and Papadimitriou, Christos and Pertesi, Maroulio and Timotheadou, Eleni and Stavropoulou, Alexandra V and Glentis, Stavros and Bournakis, Evangelos and Bobos, Mattheos and Pectasides, Dimitrios and Papakostas, Pavlos and Pentheroudakis, George and Gogas, Helen and Skarlos, Pantelis and Samantas, Epaminontas and Bafaloukos, Dimitrios and Kosmidis, Paris A and Koutras, Angelos and Yannoukakos, Drakoulis and Konstantopoulou, Irene and Fountzilas, George
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: A Hellenic cooperative oncology group (HeCOG) study
by Papaxoinis, George and Kotoula, Vassiliki and Alexopoulou, Zoi and Kalogeras, Konstantine T and Zagouri, Flora and Timotheadou, Eleni and Gogas, Helen and Pentheroudakis, George and Christodoulou, Christos and Koutras, Angelos and Bafaloukos, Dimitrios and Aravantinos, Gerasimos and Papakostas, Pavlos and Charalambous, Elpida and Papadopoulou, Kyriaki and Varthalitis, Ioannis and Efstratiou, Ioannis and Zaramboukas, Thomas and Patsea, Helen and Scopa, Chrisoula D and Skondra, Maria and Kosmidis, Paris and Pectasides, Dimitrios and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0140293
Background The PI3K-AKT pathway is frequently activated in breast cancer. PIK3CA mutations are most frequently found in the helical (exon 9) and kinase (exon... 
ANDROGEN RECEPTOR | PTEN LOSS | TRASTUZUMAB | SIGNALING PATHWAY | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | TENSIN HOMOLOG | DENSE SEQUENTIAL CHEMOTHERAPY | ASSOCIATION | PACLITAXEL | Gene mutations | Adjuvant treatment | Physiological aspects | Breast cancer | Genetic aspects | Research | Drug therapy | Cancer | Immunohistochemistry | Statistical analysis | Carcinoma | Clinical trials | AKT protein | Histology | Statistical methods | Insulin-like growth factors | Kinases | Patients | ErbB-2 protein | Subgroups | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Biomarkers | Breast | Sampling methods | Mutation | PTEN protein | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights